GSK to advance mRNA flu vaccine to late-stage trial

Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

GSK to advance mRNA flu vaccine to late-stage trial

GSK pushes 'next-generation' mRNA flu shot into phase 3

Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.

GSK to advance mRNA seasonal flu vaccine to phase 3 trial (GSK:NYSE)

GSK advances its mRNA seasonal flu vaccine FLUm3HA.b-3NA to a Phase III trial in Sept 2026 after strong Phase II results vs standard shots—read updates.

GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial

GSK's seasonal, mRNA-based influenza vaccine is progressing to a Phase III study after securing a safety and efficacy win in a mid-stage trial – potentially poising it to become a market competitor to Moderna's newly approved mRNA shot, mFlusvia. The British pharma company is opting to progress…

GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation

GSK on Tuesday said it will start a late-stage trial of its mRNA vaccine for seasonal influenza after the candidate delivered “higher immune responses” than traditional vaccines in a Phase 2 test. The UK pharma ...